GITNUXREPORT 2026

Bile Duct Cancer Statistics

Rare but deadly bile duct cancer rates are rising with sharp global variations.

Written by Isabelle Moreau·Edited by Rajesh Patel·Fact-checked by Nicholas Chambers

Published Feb 13, 2026·Last verified Apr 3, 2026·Next review: Oct 2026

How We Build This Report

Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Statistics that could not be independently verified are excluded regardless of how widely cited they are elsewhere.

Our process →

Statistic 1

Jaundice present in 75-90% of patients at diagnosis of extrahepatic cholangiocarcinoma per 2022 review

Statistic 2

Weight loss occurs in 50-70% of intrahepatic cholangiocarcinoma cases at presentation per Mayo Clinic series

Statistic 3

Abdominal pain reported by 60% of patients with perihilar tumors on diagnosis per EASL guidelines 2019

Statistic 4

Pruritus affects 25-40% of extrahepatic bile duct cancer patients due to cholestasis per UK series

Statistic 5

Anorexia and fatigue in 40-60% at diagnosis per SEER-linked symptom study 2015-2020

Statistic 6

Palpable gallbladder (Courvoisier's sign) in 15-25% of distal bile duct cancers per surgical review

Statistic 7

Elevated CA19-9 (>37 U/mL) in 85% sensitivity for cholangiocarcinoma diagnosis per meta-analysis 2021

Statistic 8

Asymptomatic presentation in 20% of intrahepatic cases found incidentally on imaging per US series

Statistic 9

Cholangitis episodes precede diagnosis in 30% of extrahepatic cases per retrospective study 1,000 pts

Statistic 10

Dark urine and pale stools in 70% of obstructive jaundice cases from bile duct tumors

Statistic 11

Median age at symptom onset 72 years for extrahepatic cholangiocarcinoma per SEER 2004-2015

Statistic 12

Hepatomegaly on exam in 45% of advanced intrahepatic cholangiocarcinoma per clinicopathologic study

Statistic 13

Median duration of symptoms before diagnosis 2-3 months for hilar tumors per Japanese registry

Statistic 14

Fever in 20-30% due to secondary infection in bile duct obstruction per review

Statistic 15

Lymphadenopathy (supraclavicular) in 10% at presentation indicating metastasis per staging study

Statistic 16

CEA elevation (>5 ng/mL) in 40-50% of cases but less specific than CA19-9 per biomarker study

Statistic 17

Ascites in 15% of patients with peritoneal involvement at diagnosis per autopsy series

Statistic 18

Paraneoplastic syndromes rare, <5%, including hypercalcemia in 2% per case reports compilation

Statistic 19

Dysphagia from esophageal varices in 5% with portal vein invasion per advanced case series

Statistic 20

Serum bilirubin >10 mg/dL in 60% of distal bile duct cancers at presentation per cohort

Statistic 21

MRI sensitivity 92% for detecting primary bile duct lesions per systematic review 50 studies

Statistic 22

Endoscopic retrograde cholangiopancreatography (ERCP) diagnostic yield 95% with brush cytology 40% sensitivity for malignancy

Statistic 23

CA19-9 specificity 82% at cutoff 100 U/mL for distinguishing benign vs malignant strictures per meta-analysis

Statistic 24

PET-CT detects metastases with 93% sensitivity in cholangiocarcinoma staging per 2020 review

Statistic 25

EUS-FNA cytology sensitivity 86% for perihilar lesions per multicenter study 300 pts

Statistic 26

Liver biopsy for intrahepatic type 85% diagnostic accuracy but 20% complication rate per guidelines

Statistic 27

MRCP sensitivity 92%, specificity 100% for ductal involvement per diagnostic accuracy meta-analysis

Statistic 28

FISH analysis on bile cytology increases sensitivity to 75% from 25% routine cytology per study

Statistic 29

CT scan detects mass-forming intrahepatic cholangiocarcinoma in 80% cases per radiology review

Statistic 30

IDH1/2 mutations detected in 13% of intrahepatic cases via NGS on biopsy per TCGA data

Statistic 31

Percutaneous transhepatic cholangiography (PTC) used in 15% failed ERCP cases with 98% success visualization

Statistic 32

Serum miR-21 elevated in 90% cholangiocarcinoma vs controls, potential biomarker per validation study

Statistic 33

Core biopsy vs FNA: 92% vs 68% sensitivity for extrahepatic lesions per comparative study

Statistic 34

70% of cases diagnosed at stage III/IV per SEER 2010-2019 due to late presentation

Statistic 35

Contrast-enhanced US sensitivity 89% for vascular invasion assessment per meta-analysis

Statistic 36

Circulating tumor DNA (ctDNA) detects 73% advanced cases with FGFR2 fusions per liquid biopsy study

Statistic 37

SpyGlass cholangioscopy biopsy sensitivity 90.6% for indeterminate strictures per multicenter trial

Statistic 38

AFP rarely elevated <10% in cholangiocarcinoma unlike HCC, aids differential per biomarker panel

Statistic 39

Lymph node biopsy positive in 40% clinically negative nodes on EUS per staging accuracy study

Statistic 40

Hepatobiliary scintigraphy (HIDA) specificity 95% for functional obstruction per nuclear med review

Statistic 41

KRAS mutations in 20-40% bile cytology aids molecular diagnosis per NGS panel validation

Statistic 42

In the United States, the incidence rate of extrahepatic bile duct cancer was 1.0 per 100,000 persons in 2020, showing a 2.5% annual increase since 2000

Statistic 43

Globally, cholangiocarcinoma accounts for 10-20% of all hepatobiliary malignancies with an estimated 8,000 new cases annually in the US as of 2022

Statistic 44

Age-adjusted incidence of intrahepatic cholangiocarcinoma rose from 0.32 per 100,000 in 1973 to 1.49 per 100,000 in 2012 in the US SEER database

Statistic 45

In Thailand, the age-standardized incidence rate of cholangiocarcinoma is 96.4 per 100,000 in males due to liver fluke infection, highest globally per 2018 GLOBOCAN data

Statistic 46

Prevalence of bile duct cancer in Europe averages 0.8-1.2 per 100,000 with higher rates in Eastern Europe at 1.8 per 100,000 per IARC 2020

Statistic 47

Among Asian Americans, intrahepatic bile duct cancer incidence is 1.5 times higher than whites at 1.2 vs 0.8 per 100,000 (SEER 2015-2019)

Statistic 48

In Japan, extrahepatic cholangiocarcinoma comprises 3% of gastrointestinal cancers with 5,000 annual cases reported in 2021 national registry

Statistic 49

UK incidence of bile duct cancer is 2.4 per million population yearly, with 680 new diagnoses in 2019 per Cancer Research UK

Statistic 50

Mortality from cholangiocarcinoma in the US increased 3.5% annually from 1973-2012, reaching 1.1 per 100,000 by 2020

Statistic 51

In Korea, cholangiocarcinoma incidence peaked at 4.5 per 100,000 in males aged 70-79 per 2019 national data

Statistic 52

Female-to-male ratio for intrahepatic cholangiocarcinoma is 1.3:1 in the US SEER data 2000-2018

Statistic 53

Global burden of cholangiocarcinoma estimated at 410,000 disability-adjusted life years lost in 2019 per Global Burden of Disease study

Statistic 54

In Louisiana, US, highest US incidence at 2.3 per 100,000 linked to environmental factors per SEER 2014-2018

Statistic 55

Incidence of perihilar cholangiocarcinoma is 0.6 per 100,000 in Western countries per 2022 systematic review

Statistic 56

In China, intrahepatic cholangiocarcinoma cases numbered 22,123 in 2020 with ASIR of 1.6 per 100,000

Statistic 57

5-year limited duration prevalence of bile duct cancer in US is 15,000 cases as of 2021 SEER estimate

Statistic 58

Age-specific incidence rises exponentially after 50 years, peaking at 8.2 per 100,000 in 80+ age group US 2019

Statistic 59

In Australia, bile duct cancer incidence is 1.0 per 100,000 with 300 annual cases per 2021 AIHW data

Statistic 60

Hispanic population in US has 1.4 per 100,000 incidence vs 0.9 for non-Hispanic whites per SEER 2015-2019

Statistic 61

Eastern England cancer registry reports 1.5 per 100,000 incidence for cholangiocarcinoma 2013-2017

Statistic 62

Lifetime risk of developing bile duct cancer is 0.013% in US males and 0.012% in females per DevCan 2022

Statistic 63

In India, cholangiocarcinoma incidence is 0.4 per 100,000 but rising 5% yearly per 2020 NCRP data

Statistic 64

Brazil reports 1,200 annual cholangiocarcinoma deaths with ASMR 0.7 per 100,000 per 2019 data

Statistic 65

In Sweden, national registry shows 250 new bile duct cancers yearly, incidence 2.4 per 100,000 2018

Statistic 66

Canadian incidence of extrahepatic bile duct cancer is 0.9 per 100,000 per 2019 CIHI data

Statistic 67

In Germany, 1,800 cholangiocarcinoma cases diagnosed in 2021 per Robert Koch Institute, ASIR 2.1/100k

Statistic 68

African Americans have 20% higher mortality rate from bile duct cancer at 1.3 vs 1.0 per 100k whites US 2019

Statistic 69

In Italy, incidence increased 4.4% annually 1990-2015 per AIRTum registry

Statistic 70

New Zealand Maori population incidence 2.1 per 100,000 vs 0.9 in Europeans per 2020 data

Statistic 71

Russia reports ASIR 2.5 per 100,000 for cholangiocarcinoma highest in Europe per GLOBOCAN 2020

Statistic 72

5-year OS post-resection 40-50% intrahepatic vs 20-30% extrahepatic per NCDB 2010-2018

Statistic 73

Unresectable disease median OS 12 months with modern systemic therapy per 2022 meta-analysis

Statistic 74

R1 resection margin 2-year OS 35% vs 60% R0 per Mayo Clinic series 500 pts

Statistic 75

Stage IA intrahepatic 5-year survival 78% vs IV 2% per AJCC 8th edition SEER validation

Statistic 76

Lymph node positivity halves 5-year OS to 15% in resected extrahepatic per meta-analysis

Statistic 77

MSI-high subset 5-year OS 53% post-immunotherapy vs 10% conventional chemo per cohort

Statistic 78

Perineural invasion present in 60% worsens median OS to 8 months advanced disease

Statistic 79

IDH1 mutated median OS 33.6 vs 20.2 mo placebo with ivosidenib (ClarIDHy)

Statistic 80

Vascular encasement >180 degrees unresectable with median OS 10 months per imaging study

Statistic 81

Elderly >75 years 1-year survival 40% vs 70% <65 post-resection per NCDB analysis

Statistic 82

FGFR2 fusion median OS 21 months targeted therapy vs 12 chemo per registry data

Statistic 83

Metastatic to liver 6-month OS 25% from extrahepatic primary per autopsy series

Statistic 84

PSC-associated cholangiocarcinoma 5-year survival 40% post-resection vs 20% sporadic

Statistic 85

CA19-9 >1000 U/mL at diagnosis median OS 6 months regardless treatment per biomarker study

Statistic 86

Intrahepatic mass-forming type 5-year OS 44% resected vs 12% palliative per Korean registry

Statistic 87

Postoperative 90-day mortality 5-10% after major hepatectomy for hilar tumors per NSQIP

Statistic 88

Oligometastatic disease median OS 20 months with aggressive local therapy per case series

Statistic 89

Biliary obstruction unrelieved median survival 1-2 months per palliative care study

Statistic 90

TP53 mutated subset poorer prognosis median OS 14 vs 24 mo wild-type per TCGA analysis

Statistic 91

Distal bile duct cancer best prognosis resected 5-year OS 40% vs hilar 25% per Japanese data

Statistic 92

Recurrence rate 70% within 2 years post-resection intrahepatic type per long-term follow-up

Statistic 93

Overall US 5-year relative survival 10% all stages combined SEER 2014-2020

Statistic 94

Lung metastasis most common 45% of metastatic sites per autopsy 200 cases

Statistic 95

Adjuvant therapy post-R0 resection improves 5-year OS to 65% from 50% surgery alone per trial

Statistic 96

Primary sclerosing cholangitis (PSC) increases risk of cholangiocarcinoma by 10-20% lifetime risk in affected patients per 2022 AASLD guidelines

Statistic 97

Chronic hepatitis C infection elevates bile duct cancer risk by 3.2-fold (RR 3.2, 95% CI 2.1-4.9) per meta-analysis of 15 studies

Statistic 98

Liver fluke (Opisthorchis viverrini) infection causes 80% of cholangiocarcinoma cases in endemic Northeast Thailand areas

Statistic 99

Diabetes mellitus type 2 associated with 1.5-2.0 increased risk of intrahepatic cholangiocarcinoma per US cohort study 10-year follow-up

Statistic 100

Obesity (BMI >30) raises risk by 1.6 times (HR 1.6, 95% CI 1.2-2.1) for extrahepatic cholangiocarcinoma per EPIC study

Statistic 101

Smoking (current) increases cholangiocarcinoma risk by 1.4-fold (OR 1.4, 95% CI 1.1-1.8) meta-analysis 20 studies

Statistic 102

Alcohol consumption >45g/day elevates risk 2.0 times for intrahepatic type per Korean case-control study

Statistic 103

Choledochal cysts confer 10-30% lifetime risk of malignant transformation to cholangiocarcinoma

Statistic 104

Hepatitis B chronic infection OR 2.7 (95% CI 1.9-3.8) for cholangiocarcinoma per meta-analysis 2019

Statistic 105

Inflammatory bowel disease (ulcerative colitis) with PSC has 31% cumulative risk at 25 years per cohort study

Statistic 106

Exposure to thorotrast (radioactive contrast) increases risk 100-fold historically, still relevant in Asia per 2021 review

Statistic 107

HIV infection associated with 3.7-fold risk (SIR 3.7, 95% CI 2.2-6.1) for cholangiocarcinoma per Danish registry

Statistic 108

Non-alcoholic fatty liver disease (NAFLD) OR 2.4 for intrahepatic cholangiocarcinoma per Italian case-control

Statistic 109

Biliary stones (cholelithiasis) increase risk 4.8-fold (OR 4.8) in low-incidence areas per meta-analysis

Statistic 110

Occupational exposure to asbestos elevates risk 2.5 times per Swedish cohort 40-year follow-up

Statistic 111

Genetic polymorphism in ABCB4 gene doubles risk in PSC patients per genome-wide study

Statistic 112

Cirrhosis from any cause increases risk 5-fold (HR 5.0, 95% CI 3.5-7.2) per US veteran cohort

Statistic 113

Clonorchis sinensis infection responsible for 15% of global cholangiocarcinoma cases per WHO 2023

Statistic 114

Metabolic syndrome components additively increase risk: hypertension OR 1.3, dyslipidemia 1.4 per study

Statistic 115

Caroli disease (congenital ductal ectasia) 7-15% risk of cholangiocarcinoma development by age 40

Statistic 116

Dioxin exposure (TCDD) from industrial accidents raises risk 3-fold long-term per Seveso cohort

Statistic 117

Family history of biliary cancers increases risk 2.2-fold per case-control study 1,000 pairs

Statistic 118

Chronic pancreatitis association OR 4.1 (95% CI 1.7-9.9) per meta-analysis 8 studies

Statistic 119

Polycyclic aromatic hydrocarbons (PAH) occupational exposure HR 1.8 in woodworkers per cohort

Statistic 120

TP53 mutations in bile duct epithelium found in 45% of fluke-associated cases vs 15% sporadic

Statistic 121

IgG4-related sclerosing cholangitis 10% progression to cholangiocarcinoma per Japanese series

Statistic 122

Surgical resection achieves R0 margins in 30-50% of hilar cholangiocarcinoma cases per international series 2022

Statistic 123

Gemcitabine-cisplatin first-line chemotherapy median OS 11.7 months vs 8.1 gem alone (ABC-02 trial n=410)

Statistic 124

Liver transplant 5-year survival 65-82% for early perihilar cholangiocarcinoma with neoadjuvant chemorad per Mayo protocol

Statistic 125

Pembrolizumab ORR 34% in MSI-high/dMMR cholangiocarcinoma (KEYNOTE-158 n=22)

Statistic 126

FGFR2 fusion-positive patients: futibatinib ORR 42% median DoR 9.7 mo (FOENIX-CCA2 trial)

Statistic 127

Stereotactic body radiotherapy (SBRT) local control 85% at 1 year for unresectable cases per meta-analysis

Statistic 128

Neoadjuvant chemotherapy downstages 25% of borderline resectable intrahepatic cases per series

Statistic 129

Durvalumab + gem/cis improves PFS HR 0.68 (TOPAZ-1 trial n=685 phase III)

Statistic 130

Hilar stenting relieves jaundice in 90% but cholangitis risk 20% at 3 months per palliative study

Statistic 131

Adjuvant capecitabine OS benefit HR 0.81 (BILCAP trial n=447 resected)

Statistic 132

Radioembolization (Y-90) median OS 14.8 months unresectable intrahepatic per SIRveXIB trial

Statistic 133

Ivosidenib ORR 32% IDH1-mutated cholangiocarcinoma (ClarIDHy trial phase III)

Statistic 134

Photodynamic therapy + stenting median survival 15 vs 6 months alone per randomized trial

Statistic 135

HER2-targeted trastuzumab deruxtecan ORR 26.3% pretreated pts per DESTINY-PanTumor02

Statistic 136

Proton beam therapy local control 91% at 2 years for hilar tumors per Japanese series

Statistic 137

Nab-paclitaxel + gemcitabine median PFS 5.7 months second-line per phase II trial

Statistic 138

Orthotopic liver transplant R0 resection 92% with strict selection per European series 100 pts

Statistic 139

TAS-102 (trifluridine-tipiracil) OS 5.7 vs 3.8 mo placebo second-line (TAS-118-02 trial)

Statistic 140

Intra-arterial chemotherapy median OS 21 months advanced disease per review 15 studies

Statistic 141

Nivolumab ORR 22% third-line (CheckMate 459 subset) but PD-L1 low response

Statistic 142

Preoperative portal vein embolization hypertrophy 40-60% future liver remnant in 4 weeks

1/142

Sources

Trusted by 500+ publications

+497

Though often overlooked, bile duct cancer's alarming 2.5% annual rise in the U.S. and staggering 96.4 per 100,000 incidence rate in parts of Thailand reveal a global health challenge hidden in plain sight.

Key Takeaways

In the United States, the incidence rate of extrahepatic bile duct cancer was 1.0 per 100,000 persons in 2020, showing a 2.5% annual increase since 2000
Globally, cholangiocarcinoma accounts for 10-20% of all hepatobiliary malignancies with an estimated 8,000 new cases annually in the US as of 2022
Age-adjusted incidence of intrahepatic cholangiocarcinoma rose from 0.32 per 100,000 in 1973 to 1.49 per 100,000 in 2012 in the US SEER database
Primary sclerosing cholangitis (PSC) increases risk of cholangiocarcinoma by 10-20% lifetime risk in affected patients per 2022 AASLD guidelines
Chronic hepatitis C infection elevates bile duct cancer risk by 3.2-fold (RR 3.2, 95% CI 2.1-4.9) per meta-analysis of 15 studies
Liver fluke (Opisthorchis viverrini) infection causes 80% of cholangiocarcinoma cases in endemic Northeast Thailand areas
Jaundice present in 75-90% of patients at diagnosis of extrahepatic cholangiocarcinoma per 2022 review
Weight loss occurs in 50-70% of intrahepatic cholangiocarcinoma cases at presentation per Mayo Clinic series
Abdominal pain reported by 60% of patients with perihilar tumors on diagnosis per EASL guidelines 2019
MRI sensitivity 92% for detecting primary bile duct lesions per systematic review 50 studies
Endoscopic retrograde cholangiopancreatography (ERCP) diagnostic yield 95% with brush cytology 40% sensitivity for malignancy
CA19-9 specificity 82% at cutoff 100 U/mL for distinguishing benign vs malignant strictures per meta-analysis
Surgical resection achieves R0 margins in 30-50% of hilar cholangiocarcinoma cases per international series 2022
Gemcitabine-cisplatin first-line chemotherapy median OS 11.7 months vs 8.1 gem alone (ABC-02 trial n=410)
Liver transplant 5-year survival 65-82% for early perihilar cholangiocarcinoma with neoadjuvant chemorad per Mayo protocol

Rare but deadly bile duct cancer rates are rising with sharp global variations.

Clinical Presentation

1Jaundice present in 75-90% of patients at diagnosis of extrahepatic cholangiocarcinoma per 2022 review

Verified

2Weight loss occurs in 50-70% of intrahepatic cholangiocarcinoma cases at presentation per Mayo Clinic series

Verified

3Abdominal pain reported by 60% of patients with perihilar tumors on diagnosis per EASL guidelines 2019

Verified

4Pruritus affects 25-40% of extrahepatic bile duct cancer patients due to cholestasis per UK series

Directional

5Anorexia and fatigue in 40-60% at diagnosis per SEER-linked symptom study 2015-2020

Single source

6Palpable gallbladder (Courvoisier's sign) in 15-25% of distal bile duct cancers per surgical review

Verified

7Elevated CA19-9 (>37 U/mL) in 85% sensitivity for cholangiocarcinoma diagnosis per meta-analysis 2021

Verified

8Asymptomatic presentation in 20% of intrahepatic cases found incidentally on imaging per US series

Verified

9Cholangitis episodes precede diagnosis in 30% of extrahepatic cases per retrospective study 1,000 pts

Directional

10Dark urine and pale stools in 70% of obstructive jaundice cases from bile duct tumors

Single source

11Median age at symptom onset 72 years for extrahepatic cholangiocarcinoma per SEER 2004-2015

Verified

12Hepatomegaly on exam in 45% of advanced intrahepatic cholangiocarcinoma per clinicopathologic study

Verified

13Median duration of symptoms before diagnosis 2-3 months for hilar tumors per Japanese registry

Verified

14Fever in 20-30% due to secondary infection in bile duct obstruction per review

Directional

15Lymphadenopathy (supraclavicular) in 10% at presentation indicating metastasis per staging study

Single source

16CEA elevation (>5 ng/mL) in 40-50% of cases but less specific than CA19-9 per biomarker study

Verified

17Ascites in 15% of patients with peritoneal involvement at diagnosis per autopsy series

Verified

18Paraneoplastic syndromes rare, <5%, including hypercalcemia in 2% per case reports compilation

Verified

19Dysphagia from esophageal varices in 5% with portal vein invasion per advanced case series

Directional

20Serum bilirubin >10 mg/dL in 60% of distal bile duct cancers at presentation per cohort

Single source

Clinical Presentation Interpretation

While the statistics paint a grim portrait of jaundice, fatigue, and fleeting time before diagnosis, this cancer’s insidious nature is underscored by the fact that one in five patients with the intrahepatic form feel perfectly fine as it silently takes hold.

Diagnosis

1MRI sensitivity 92% for detecting primary bile duct lesions per systematic review 50 studies

Verified

2Endoscopic retrograde cholangiopancreatography (ERCP) diagnostic yield 95% with brush cytology 40% sensitivity for malignancy

Verified

3CA19-9 specificity 82% at cutoff 100 U/mL for distinguishing benign vs malignant strictures per meta-analysis

Verified

4PET-CT detects metastases with 93% sensitivity in cholangiocarcinoma staging per 2020 review

Directional

5EUS-FNA cytology sensitivity 86% for perihilar lesions per multicenter study 300 pts

Single source

6Liver biopsy for intrahepatic type 85% diagnostic accuracy but 20% complication rate per guidelines

Verified

7MRCP sensitivity 92%, specificity 100% for ductal involvement per diagnostic accuracy meta-analysis

Verified

8FISH analysis on bile cytology increases sensitivity to 75% from 25% routine cytology per study

Verified

9CT scan detects mass-forming intrahepatic cholangiocarcinoma in 80% cases per radiology review

Directional

10IDH1/2 mutations detected in 13% of intrahepatic cases via NGS on biopsy per TCGA data

Single source

11Percutaneous transhepatic cholangiography (PTC) used in 15% failed ERCP cases with 98% success visualization

Verified

12Serum miR-21 elevated in 90% cholangiocarcinoma vs controls, potential biomarker per validation study

Verified

13Core biopsy vs FNA: 92% vs 68% sensitivity for extrahepatic lesions per comparative study

Verified

1470% of cases diagnosed at stage III/IV per SEER 2010-2019 due to late presentation

Directional

15Contrast-enhanced US sensitivity 89% for vascular invasion assessment per meta-analysis

Single source

16Circulating tumor DNA (ctDNA) detects 73% advanced cases with FGFR2 fusions per liquid biopsy study

Verified

17SpyGlass cholangioscopy biopsy sensitivity 90.6% for indeterminate strictures per multicenter trial

Verified

18AFP rarely elevated <10% in cholangiocarcinoma unlike HCC, aids differential per biomarker panel

Verified

19Lymph node biopsy positive in 40% clinically negative nodes on EUS per staging accuracy study

Directional

20Hepatobiliary scintigraphy (HIDA) specificity 95% for functional obstruction per nuclear med review

Single source

21KRAS mutations in 20-40% bile cytology aids molecular diagnosis per NGS panel validation

Verified

Diagnosis Interpretation

In the intricate maze of cholangiocarcinoma diagnosis, no single test is a perfect guide, but together they form a formidable toolkit where imaging paints a broad picture, scopes and biopsies provide critical confirmations, and molecular clues increasingly illuminate the path—though all are tragically often deployed too late to change the dismal staging statistics.

Epidemiology

1In the United States, the incidence rate of extrahepatic bile duct cancer was 1.0 per 100,000 persons in 2020, showing a 2.5% annual increase since 2000

Verified

2Globally, cholangiocarcinoma accounts for 10-20% of all hepatobiliary malignancies with an estimated 8,000 new cases annually in the US as of 2022

Verified

3Age-adjusted incidence of intrahepatic cholangiocarcinoma rose from 0.32 per 100,000 in 1973 to 1.49 per 100,000 in 2012 in the US SEER database

Verified

4In Thailand, the age-standardized incidence rate of cholangiocarcinoma is 96.4 per 100,000 in males due to liver fluke infection, highest globally per 2018 GLOBOCAN data

Directional

5Prevalence of bile duct cancer in Europe averages 0.8-1.2 per 100,000 with higher rates in Eastern Europe at 1.8 per 100,000 per IARC 2020

Single source

6Among Asian Americans, intrahepatic bile duct cancer incidence is 1.5 times higher than whites at 1.2 vs 0.8 per 100,000 (SEER 2015-2019)

Verified

7In Japan, extrahepatic cholangiocarcinoma comprises 3% of gastrointestinal cancers with 5,000 annual cases reported in 2021 national registry

Verified

8UK incidence of bile duct cancer is 2.4 per million population yearly, with 680 new diagnoses in 2019 per Cancer Research UK

Verified

9Mortality from cholangiocarcinoma in the US increased 3.5% annually from 1973-2012, reaching 1.1 per 100,000 by 2020

Directional

10In Korea, cholangiocarcinoma incidence peaked at 4.5 per 100,000 in males aged 70-79 per 2019 national data

Single source

11Female-to-male ratio for intrahepatic cholangiocarcinoma is 1.3:1 in the US SEER data 2000-2018

Verified

12Global burden of cholangiocarcinoma estimated at 410,000 disability-adjusted life years lost in 2019 per Global Burden of Disease study

Verified

13In Louisiana, US, highest US incidence at 2.3 per 100,000 linked to environmental factors per SEER 2014-2018

Verified

14Incidence of perihilar cholangiocarcinoma is 0.6 per 100,000 in Western countries per 2022 systematic review

Directional

15In China, intrahepatic cholangiocarcinoma cases numbered 22,123 in 2020 with ASIR of 1.6 per 100,000

Single source

165-year limited duration prevalence of bile duct cancer in US is 15,000 cases as of 2021 SEER estimate

Verified

17Age-specific incidence rises exponentially after 50 years, peaking at 8.2 per 100,000 in 80+ age group US 2019

Verified

18In Australia, bile duct cancer incidence is 1.0 per 100,000 with 300 annual cases per 2021 AIHW data

Verified

19Hispanic population in US has 1.4 per 100,000 incidence vs 0.9 for non-Hispanic whites per SEER 2015-2019

Directional

20Eastern England cancer registry reports 1.5 per 100,000 incidence for cholangiocarcinoma 2013-2017

Single source

21Lifetime risk of developing bile duct cancer is 0.013% in US males and 0.012% in females per DevCan 2022

Verified

22In India, cholangiocarcinoma incidence is 0.4 per 100,000 but rising 5% yearly per 2020 NCRP data

Verified

23Brazil reports 1,200 annual cholangiocarcinoma deaths with ASMR 0.7 per 100,000 per 2019 data

Verified

24In Sweden, national registry shows 250 new bile duct cancers yearly, incidence 2.4 per 100,000 2018

Directional

25Canadian incidence of extrahepatic bile duct cancer is 0.9 per 100,000 per 2019 CIHI data

Single source

26In Germany, 1,800 cholangiocarcinoma cases diagnosed in 2021 per Robert Koch Institute, ASIR 2.1/100k

Verified

27African Americans have 20% higher mortality rate from bile duct cancer at 1.3 vs 1.0 per 100k whites US 2019

Verified

28In Italy, incidence increased 4.4% annually 1990-2015 per AIRTum registry

Verified

29New Zealand Maori population incidence 2.1 per 100,000 vs 0.9 in Europeans per 2020 data

Directional

30Russia reports ASIR 2.5 per 100,000 for cholangiocarcinoma highest in Europe per GLOBOCAN 2020

Single source

Epidemiology Interpretation

The numbers weave a quiet but persistent tragedy, revealing that while bile duct cancer remains rare overall, its stealthy rise in specific populations—from the liver fluke-ravaged regions of Thailand to the bayous of Louisiana—demands a global and locally-tailored vigilance.

Prognosis

15-year OS post-resection 40-50% intrahepatic vs 20-30% extrahepatic per NCDB 2010-2018

Verified

2Unresectable disease median OS 12 months with modern systemic therapy per 2022 meta-analysis

Verified

3R1 resection margin 2-year OS 35% vs 60% R0 per Mayo Clinic series 500 pts

Verified

4Stage IA intrahepatic 5-year survival 78% vs IV 2% per AJCC 8th edition SEER validation

Directional

5Lymph node positivity halves 5-year OS to 15% in resected extrahepatic per meta-analysis

Single source

6MSI-high subset 5-year OS 53% post-immunotherapy vs 10% conventional chemo per cohort

Verified

7Perineural invasion present in 60% worsens median OS to 8 months advanced disease

Verified

8IDH1 mutated median OS 33.6 vs 20.2 mo placebo with ivosidenib (ClarIDHy)

Verified

9Vascular encasement >180 degrees unresectable with median OS 10 months per imaging study

Directional

10Elderly >75 years 1-year survival 40% vs 70% <65 post-resection per NCDB analysis

Single source

11FGFR2 fusion median OS 21 months targeted therapy vs 12 chemo per registry data

Verified

12Metastatic to liver 6-month OS 25% from extrahepatic primary per autopsy series

Verified

13PSC-associated cholangiocarcinoma 5-year survival 40% post-resection vs 20% sporadic

Verified

14CA19-9 >1000 U/mL at diagnosis median OS 6 months regardless treatment per biomarker study

Directional

15Intrahepatic mass-forming type 5-year OS 44% resected vs 12% palliative per Korean registry

Single source

16Postoperative 90-day mortality 5-10% after major hepatectomy for hilar tumors per NSQIP

Verified

17Oligometastatic disease median OS 20 months with aggressive local therapy per case series

Verified

18Biliary obstruction unrelieved median survival 1-2 months per palliative care study

Verified

19TP53 mutated subset poorer prognosis median OS 14 vs 24 mo wild-type per TCGA analysis

Directional

20Distal bile duct cancer best prognosis resected 5-year OS 40% vs hilar 25% per Japanese data

Single source

21Recurrence rate 70% within 2 years post-resection intrahepatic type per long-term follow-up

Verified

22Overall US 5-year relative survival 10% all stages combined SEER 2014-2020

Verified

23Lung metastasis most common 45% of metastatic sites per autopsy 200 cases

Verified

24Adjuvant therapy post-R0 resection improves 5-year OS to 65% from 50% surgery alone per trial

Directional

Prognosis Interpretation

These statistics paint a stark portrait of bile duct cancer: a relentless disease where early detection and a clean resection offer a glimmer of hope, but where the margins for success are heartbreakingly thin and often measured in single percentage points.

Risk Factors

1Primary sclerosing cholangitis (PSC) increases risk of cholangiocarcinoma by 10-20% lifetime risk in affected patients per 2022 AASLD guidelines

Verified

2Chronic hepatitis C infection elevates bile duct cancer risk by 3.2-fold (RR 3.2, 95% CI 2.1-4.9) per meta-analysis of 15 studies

Verified

3Liver fluke (Opisthorchis viverrini) infection causes 80% of cholangiocarcinoma cases in endemic Northeast Thailand areas

Verified

4Diabetes mellitus type 2 associated with 1.5-2.0 increased risk of intrahepatic cholangiocarcinoma per US cohort study 10-year follow-up

Directional

5Obesity (BMI >30) raises risk by 1.6 times (HR 1.6, 95% CI 1.2-2.1) for extrahepatic cholangiocarcinoma per EPIC study

Single source

6Smoking (current) increases cholangiocarcinoma risk by 1.4-fold (OR 1.4, 95% CI 1.1-1.8) meta-analysis 20 studies

Verified

7Alcohol consumption >45g/day elevates risk 2.0 times for intrahepatic type per Korean case-control study

Verified

8Choledochal cysts confer 10-30% lifetime risk of malignant transformation to cholangiocarcinoma

Verified

9Hepatitis B chronic infection OR 2.7 (95% CI 1.9-3.8) for cholangiocarcinoma per meta-analysis 2019

Directional

10Inflammatory bowel disease (ulcerative colitis) with PSC has 31% cumulative risk at 25 years per cohort study

Single source

11Exposure to thorotrast (radioactive contrast) increases risk 100-fold historically, still relevant in Asia per 2021 review

Verified

12HIV infection associated with 3.7-fold risk (SIR 3.7, 95% CI 2.2-6.1) for cholangiocarcinoma per Danish registry

Verified

13Non-alcoholic fatty liver disease (NAFLD) OR 2.4 for intrahepatic cholangiocarcinoma per Italian case-control

Verified

14Biliary stones (cholelithiasis) increase risk 4.8-fold (OR 4.8) in low-incidence areas per meta-analysis

Directional

15Occupational exposure to asbestos elevates risk 2.5 times per Swedish cohort 40-year follow-up

Single source

16Genetic polymorphism in ABCB4 gene doubles risk in PSC patients per genome-wide study

Verified

17Cirrhosis from any cause increases risk 5-fold (HR 5.0, 95% CI 3.5-7.2) per US veteran cohort

Verified

18Clonorchis sinensis infection responsible for 15% of global cholangiocarcinoma cases per WHO 2023

Verified

19Metabolic syndrome components additively increase risk: hypertension OR 1.3, dyslipidemia 1.4 per study

Directional

20Caroli disease (congenital ductal ectasia) 7-15% risk of cholangiocarcinoma development by age 40

Single source

21Dioxin exposure (TCDD) from industrial accidents raises risk 3-fold long-term per Seveso cohort

Verified

22Family history of biliary cancers increases risk 2.2-fold per case-control study 1,000 pairs

Verified

23Chronic pancreatitis association OR 4.1 (95% CI 1.7-9.9) per meta-analysis 8 studies

Verified

24Polycyclic aromatic hydrocarbons (PAH) occupational exposure HR 1.8 in woodworkers per cohort

Directional

25TP53 mutations in bile duct epithelium found in 45% of fluke-associated cases vs 15% sporadic

Single source

26IgG4-related sclerosing cholangitis 10% progression to cholangiocarcinoma per Japanese series

Verified

Risk Factors Interpretation

The path to bile duct cancer is a grim lottery where you can unfortunately hold many tickets, from the smoking and drinking you might control to the parasites and genes you don't.

Treatment

1Surgical resection achieves R0 margins in 30-50% of hilar cholangiocarcinoma cases per international series 2022

Verified

2Gemcitabine-cisplatin first-line chemotherapy median OS 11.7 months vs 8.1 gem alone (ABC-02 trial n=410)

Verified

3Liver transplant 5-year survival 65-82% for early perihilar cholangiocarcinoma with neoadjuvant chemorad per Mayo protocol

Verified

4Pembrolizumab ORR 34% in MSI-high/dMMR cholangiocarcinoma (KEYNOTE-158 n=22)

Directional

5FGFR2 fusion-positive patients: futibatinib ORR 42% median DoR 9.7 mo (FOENIX-CCA2 trial)

Single source

6Stereotactic body radiotherapy (SBRT) local control 85% at 1 year for unresectable cases per meta-analysis

Verified

7Neoadjuvant chemotherapy downstages 25% of borderline resectable intrahepatic cases per series

Verified

8Durvalumab + gem/cis improves PFS HR 0.68 (TOPAZ-1 trial n=685 phase III)

Verified

9Hilar stenting relieves jaundice in 90% but cholangitis risk 20% at 3 months per palliative study

Directional

10Adjuvant capecitabine OS benefit HR 0.81 (BILCAP trial n=447 resected)

Single source

11Radioembolization (Y-90) median OS 14.8 months unresectable intrahepatic per SIRveXIB trial

Verified

12Ivosidenib ORR 32% IDH1-mutated cholangiocarcinoma (ClarIDHy trial phase III)

Verified

13Photodynamic therapy + stenting median survival 15 vs 6 months alone per randomized trial

Verified

14HER2-targeted trastuzumab deruxtecan ORR 26.3% pretreated pts per DESTINY-PanTumor02

Directional

15Proton beam therapy local control 91% at 2 years for hilar tumors per Japanese series

Single source

16Nab-paclitaxel + gemcitabine median PFS 5.7 months second-line per phase II trial

Verified

17Orthotopic liver transplant R0 resection 92% with strict selection per European series 100 pts

Verified

18TAS-102 (trifluridine-tipiracil) OS 5.7 vs 3.8 mo placebo second-line (TAS-118-02 trial)

Verified

19Intra-arterial chemotherapy median OS 21 months advanced disease per review 15 studies

Directional

20Nivolumab ORR 22% third-line (CheckMate 459 subset) but PD-L1 low response

Single source

21Preoperative portal vein embolization hypertrophy 40-60% future liver remnant in 4 weeks

Verified

Treatment Interpretation

Despite modest gains in surgery and targeted therapies, treating bile duct cancer remains a delicate high-wire act where buying a year is a victory, a complication is around the corner, and success hinges on picking the right weapon from an increasingly complex arsenal for the right patient at the right time.